GlassScriptPhysician profile
Vanessa Marie Green
NPI 1023850930
$1,180.66
in general payments reported to CMS, 2019-2025
24 companies · $1,022 in 2025
The $1,022 reported for 2025 was more than what 85% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $158 · 2025: $1,022.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $911 · Education: $270.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $910.68 |
| Education | $269.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $221.79 | 2025 | Rybrevant, Erleada, Carvykti |
| Daiichi Sankyo INC. | $179.45 | 2025 | Enhertu, Datroway |
| Incyte Corporation | $142.45 | 2024-2025 | Monjuvi, Jakafi |
| Novartis Pharmaceuticals Corporation | $73.06 | 2024-2025 | |
| Abbvie INC. | $66.75 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $53.04 | 2024-2025 | Opdivo |
| Genzyme Corporation | $37.32 | 2025 | |
| Karyopharm Therapeutics INC. | $33.97 | 2024 | Xpovio |
| Inari Medical, INC. | $33.27 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Springworks Therapeutics, INC. | $29.39 | 2025 | Ogsiveo |
| Adc Therapeutics America, INC. | $28.75 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.29 | 2025 | Fruzaqla |
| Geron Corporation | $27.25 | 2025 | Rytelo |
| Beone Medicines USA, INC. | $26.91 | 2025 | Brukinsa |
| Astellas Pharma US INC | $25.66 | 2025 | Vyloy |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Syndax Pharmaceuticals, INC. | $25.39 | 2025 | |
| Eisai INC. | $25.34 | 2025 | |
| Merck Sharp & Dohme LLC | $24.40 | 2025 | Keytruda |
| Array Biopharma INC | $21.04 | 2025 | Mektovi, Tukysa, Braftovi |
| Aveo Pharmaceuticals, INC. | $18.54 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.89 | 2025 | |
| Pfizer INC. | $14.18 | 2025 | |
| Agios Pharmaceuticals, INC. | $13.85 | 2025 | Pyrukynd |
| Genentech USA, INC. | $13.68 | 2025 | Tecentriq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vanessa Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.